Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.
2.

Pharmacodynamic model for chemotherapy-induced anemia in rats.

Woo S, Krzyzanski W, Jusko WJ.

Cancer Chemother Pharmacol. 2008 Jun;62(1):123-33. Epub 2007 Sep 22.

3.

Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors and plasma lipid dynamics in rats.

Hazra A, Pyszczynski NA, DuBois DC, Almon RR, Jusko WJ.

Pharm Res. 2008 Apr;25(4):769-80. Epub 2007 Aug 3.

4.
5.

Time-series modeling of multiple sclerosis disease activity: a promising window on disease progression and repair potential?

Meier DS, Weiner HL, Guttmann CR.

Neurotherapeutics. 2007 Jul;4(3):485-98. Review.

PMID:
17599713
6.

Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids.

Hazra A, Pyszczynski N, DuBois DC, Almon RR, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):643-67. Epub 2007 Jun 26.

7.

Model-based drug development.

Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R.

Clin Pharmacol Ther. 2007 Jul;82(1):21-32. Epub 2007 May 23. Review.

PMID:
17522597
8.

Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling.

Hazra A, DuBois DC, Almon RR, Jusko WJ.

J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):333-54. Epub 2007 Feb 7.

9.

Paving the critical path: how can clinical pharmacology help achieve the vision?

Lesko LJ.

Clin Pharmacol Ther. 2007 Feb;81(2):170-7. Review.

PMID:
17259944
10.

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Holford NH, Chan PL, Nutt JG, Kieburtz K, Shoulson I; Parkinson Study Group..

J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):281-311. Epub 2006 Apr 20.

PMID:
16625427
11.

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M.

J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):313-43. Epub 2006 Mar 22.

PMID:
16552630
12.

PIXImus bone densitometer and associated technical measurement issues of skeletal growth in the young rat.

Soon G, Quintin A, Scalfo F, Antille N, Williamson G, Offord E, Ginty F.

Calcif Tissue Int. 2006 Mar;78(3):186-92. Epub 2006 Mar 17.

PMID:
16547639
13.

Glucocorticoid-induced bone loss in dermatologic patients: an update.

Summey BT, Yosipovitch G.

Arch Dermatol. 2006 Jan;142(1):82-90. Review.

PMID:
16415391
16.

Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW.

Ann Rheum Dis. 2006 Mar;65(3):285-93. Epub 2005 Aug 17. Review.

17.

A dynamic population model of disease progression in COPD.

Hoogendoorn M, Rutten-van Mölken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, Feenstra TL.

Eur Respir J. 2005 Aug;26(2):223-33.

18.

Stability of dexamethasone sodium phosphate in rat plasma.

Samtani MN, Jusko WJ.

Int J Pharm. 2005 Sep 14;301(1-2):262-6.

19.

Disease system analysis: basic disease progression models in degenerative disease.

Post TM, Freijer JI, DeJongh J, Danhof M.

Pharm Res. 2005 Jul;22(7):1038-49. Epub 2005 Jul 22.

PMID:
16028004
20.

A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

Pillai G, Gieschke R, Goggin T, Jacqmin P, Schimmer RC, Steimer JL.

Br J Clin Pharmacol. 2004 Dec;58(6):618-31.

Supplemental Content

Support Center